English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

The recent studies on Nimbolide, a robust cervical anticancer agent was identified for the separation of Nimbolide from Azadirachta indica berry collected from Ranga ReddyDist, the seeds were initially isolated, dried and transformed into coarse powder. The seed core was defatted and concentrated using methanol in a soxhlet apparatus. The methanolic extract obtained from seeds is subjected to High Performance Liquid Chromatography [HPLC] by direct reverse phase method for isolation of Nimbolide using Molecular Docking of Nimbolide through Molecular Operatin Environment [MOE] 2008 software. This declared that Nimbolide has capability of binding 12.3% to a Glycine 131 undergoing polar interactions. Nimbolide was found to interact with Cyclin E, was redeemed from the Protein Data Bank [PDB code; 1W98]. It was observed that Nimbolide showed an satisfactory increased life span (54.32 and 65.16), decreased the viable cells (52.3±1.5 and 32.5±1.3), and tumor volume (3.2±0.03 and 2.4±0.04).

Development of Nimbolide from Seeds of Azadirachta Indica Extract Assisted by Molecular Docking to Cyclin E, against Cervical Cancer